FDA undecided on UniQure Huntington’s therapy; no proven benefit blocks marketing filing
An FDA official indicated UniQure’s Huntington’s disease therapy showed no demonstrated benefit based on current data, preventing a marketing application; the company disputes the assessment but hopes to align trial parameters for a potential future study.
